CART-19 cell

CART-19 cell (CD19-directed chimeric antigen receptor T-cell) therapy is an autologous cell therapy designed to target and eliminate CD19-expressing B-cell malignancies. The therapy involves isolating a patient's T-cells, genetically engineering them using a viral vector (typically lentivirus or retrovirus) to express a chimeric antigen receptor (CAR) specific for CD19, and reinfusing them back into the patient. The CAR construct typically consists of an anti-CD19 single-chain variable fragment (scFv) linked to a costimulatory domain (such as 4-1BB/CD137 or CD28) and the CD3ζ signaling domain. CART-19 cell therapy is widely investigated and approved for various B-cell malignancies, including B-cell acute lymphoblastic leukemia (B-ALL), chronic lymphocytic leukemia (CLL), and various B-cell lymphomas. In China, Luoyang Central Hospital, in collaboration with Henan Huarong Biotechnology, has evaluated CART-19 cell therapy in clinical trials (such as ChiCTR1800018211) for relapsed or refractory B-cell leukemia and lymphoma.

Other names

CART-19CART19CART 19CART19 cellCART-19 cellCART 19 cellCD19 CAR-TCD-19 CAR-TCD 19 CAR-TCD19 CAR-T cellCD-19 CAR-T cellCD 19 CAR-T cellCD19-directed CAR-T cellCD-19-directed CAR-T cellCD 19-directed CAR-T cellanti-CD19 CAR-T cellanti-CD-19 CAR-T cellanti-CD 19 CAR-T cellanti-CD19 chimeric antigen receptor T cellanti-CD-19 chimeric antigen receptor T cellanti-CD 19 chimeric antigen receptor T cell